1. Home
  2. CIG vs IBRX Comparison

CIG vs IBRX Comparison

Compare CIG & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Comp En De Mn Cemig ADS

CIG

Comp En De Mn Cemig ADS

HOLD

Current Price

$2.19

Market Cap

5.8B

Sector

Utilities

ML Signal

HOLD

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$9.97

Market Cap

6.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CIG
IBRX
Founded
1952
2014
Country
Brazil
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
6.1B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
CIG
IBRX
Price
$2.19
$9.97
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$12.60
AVG Volume (30 Days)
5.1M
31.4M
Earning Date
01-01-0001
05-18-2026
Dividend Yield
11.31%
N/A
EPS Growth
N/A
38.71
EPS
N/A
N/A
Revenue
N/A
$113,288,000.00
Revenue This Year
$0.38
$93.25
Revenue Next Year
N/A
$149.39
P/E Ratio
$9.38
N/A
Revenue Growth
N/A
668.31
52 Week Low
$1.59
$1.83
52 Week High
$2.41
$12.43

Technical Indicators

Market Signals
Indicator
CIG
IBRX
Relative Strength Index (RSI) 45.94 64.84
Support Level $1.92 $2.23
Resistance Level $2.28 N/A
Average True Range (ATR) 0.06 1.31
MACD -0.01 0.12
Stochastic Oscillator 22.41 62.08

Price Performance

Historical Comparison
CIG
IBRX

About CIG Comp En De Mn Cemig ADS

Cia Energetica DE Minas Gerais - Cemig, formerly Energy Company of Minas Gerais, is a Brazilian power company that generates, transmits, and distributes electricity. As one of the power companies in Brazil, the firm operates across Brazilian states and Chile. The company has various subsidiaries and operates chiefly through its generation, transmission, distribution, and gas segments. The majority of the company's revenue is derived from electricity sales to consumers. The company generates power through hydroelectric resources and, secondarily, through thermal and wind resources.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Share on Social Networks: